AC Immune S.A. (ACIU) vs Inhibikase Therapeutics, Inc. (IKT)
A side-by-side comparison of AC Immune S.A. and Inhibikase Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACIU
AC Immune S.A.
$2.56HealthcareDelayed quote: Oct 6, 2026, 11:34 AM EDT
IKT
Inhibikase Therapeutics, Inc.
$2.00HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
Total return — ACIU vs IKT
growth of $100 · dividends reinvested · last 6yACIU -49.8% (-10.9%/yr)IKT -96.6% (-43.2%/yr)ACIU compounded faster over this window
Log scale — wide-divergence pair
ACIU IKT
ACIU vs IKT: by the numbers
- •IKT is the larger company ($263M vs $260M market cap).
- •Both run net losses; IKT's is the smaller (0.00% vs -249.94% net margin).
Metrics side by side
Valuation
| Metric | ACIU | IKT |
|---|---|---|
| P/S ratio | 11.98 | N/A |
| P/B ratio | 5.98 | 1.72 |
Profitability
| Metric | ACIU | IKT |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -1927.32% | 0.00% |
| Net margin | -249.94% | 0.00% |
| ROE | -124.67% | -39.55% |
| ROIC | -89.43% | -42.92% |
Growth (annualized)
| Metric | ACIU | IKT |
|---|---|---|
| Revenue CAGR (5Y) | -23.70% | N/A |
| Total return CAGR (5Y) | -16.03% | -29.10% |
Frequently asked
- How have ACIU and IKT total returns compared?
- Over the past 5 years, ACIU delivered -16.03% and IKT delivered -29.10% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.